Historically, monoclonal antibodies, such as blockbuster drug, Humira®, have performed as the best-selling drugs in the world. Targeting across multi-indications such as autoimmune disorders and degenerative diseases, these drugs have multi-billion dollar blockbuster potential. But did you know, that to this day, no drug on the market is a fully human, anti-CD3 monoclonal antibody? This may change thanks to one little-known NASDAQ company that has a drug in clinical development that is the world’s ONLY full human anti-CD3 monoclonal antibody!
This company has the potential to revolutionize the way immunotherapies are currently conducted with its game-changing approach to attacking neurodegenerative diseases and lung diseases. The company’s drug is a First-in-class asset that is gaining global recognition with articles featured in Forbes and Jama Network! Similar monoclonal antibody drugs, such as Humira®, have performed extraordinarily well with approximately 200 billion dollars in revenue. With three clinical trials across neurodegenerative, autoimmune, and lung disease indications, the company is attacking multiple indications and should be high on your radar!
Discover how with an impressive team and board of scientists, this underfollowed company aims to disrupt biopharma with its potentially breakthrough therapies all while building shareholder value!
